FDA Brief

Warning letters Drugs

FDA warning letter to

Wuxi Medical Instrument Factory Co., Ltd.

High riskIssued Apr 4, 2025Posted May 20, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.

What happened

FDA inspected the Wuxi, China drug manufacturing facility from November 11 to 15, 2024. Investigators found dead insects in active-ingredient transfer tubing, debris in solution going to a filling machine, cracked or leaking tubing, and dirty ceilings above filling machines. The firm also lacked sterility testing and sterilization controls for products labeled sterile, and FDA placed its products on Import Alert 66-40 after a voluntary recall.

What FDA found

  1. FDA found insanitary conditions, including dead insects in active-ingredient transfer tubing and debris in solution being filled into products labeled sterile.

    FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)
  2. The firm did not establish and follow written procedures to prevent microbiological contamination of sterile drugs, including sterilization validation.

    21 CFR 211.113(b)
  3. The firm distributed a product labeled sterile without performing sterility testing.

    21 CFR 211.167(a)
  4. The firm relied only on supplier certificates of analysis and did not test components for identity, purity, strength, and quality or qualify the supplier.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. The firm assigned a long expiration date with only limited stability data and lacked ongoing stability testing.

    21 CFR 211.166(a)

What FDA wants

FDA asks the firm to respond in writing within 15 working days, correct the violations, and provide detailed remediation plans, including an independent contamination risk assessment and sterility validation.

Who should pay attention

  • hospitals and clinics that buy sterile drugs
  • distributors and importers of drugs from this firm
  • contract manufacturers or brands relying on similar sterility controls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk